Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
Open Access
- 6 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 892199
Abstract
Background: Pimavanserin prolongs the QT interval, with mean increases in corrected QT (QTc) of 5–8 ms, and is currently being investigated for the treatment of negative symptoms of schizophrenia.Objectives: To assess QT interval prolongation in 3 studies investigating once-daily pimavanserin as an adjunct to current antipsychotic treatment in patients with schizophrenia.Methods: Electrocardiograms were unblinded from trials in which pimavanserin or placebo was added to main antipsychotics over 6 weeks (ENHANCE), 26 weeks (ADVANCE), and up to 78 weeks (ongoing 52-week, open-label extension study [study 035]) of treatment. Antipsychotic treatment was permitted throughout these studies. The 3 most frequently used antipsychotic treatments were examined—aripiprazole (including long-acting injectable), risperidone (including long-acting injectable), and olanzapine. QT intervals were corrected (QTc) using Fridericia's method, with elevated risk defined as either postbaseline value maximum of >500 ms or change from baseline to postbaseline maximum of >60 ms.Results: Of patients treated with adjunctive pimavanserin in ENHANCE, there were no postbaseline QTc values >481 ms; one patient in each of the risperidone and aripiprazole groups had change from baseline to postbaseline maximum >60 ms. More patients had change from baseline to postbaseline maximum ranging from 31 to 60 ms in the risperidone plus adjunctive placebo group (n = 5; 6.6%) than those in the risperidone plus adjunctive pimavanserin group (n = 3, 4.1%). In the pimavanserin plus antipsychotic group of ADVANCE, one patient had postbaseline QTc value >481 ms, and one patient treated with aripiprazole had change from baseline to postbaseline maximum of >60 ms. In study 035, a change from double-blind baseline to overall postbaseline maximum >60 ms occurred in one patient treated with aripiprazole and pimavanserin and in one patient treated with risperidone and pimavanserin. Similar proportions of patients had changes from double-blind baseline to post double-blind baseline maximum between 31 and 60 ms across treatments. No adverse events associated with an increase in the QTc interval were reported.Conclusions: Adjunctive pimavanserin with background antipsychotic treatment showed no evidence of QTc prolongation >500 ms postbaseline, consistent with previously reports on QT prolongation with pimavanserin.Keywords
Funding Information
- ACADIA Pharmaceuticals
This publication has 18 references indexed in Scilit:
- Premature Mortality Among Adults With Schizophrenia in the United StatesJAMA Psychiatry, 2015
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trialThe Lancet, 2014
- Treatment of Psychosis and Dementia in Parkinson’s DiseaseCurrent Treatment Options in Neurology, 2014
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry, 2013
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- QTc Prolongation, Torsades de Pointes, and Psychotropic MedicationsPsychosomatics, 2013
- Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009Schizophrenia Research, 2012
- Electrocardiographic QT Interval and MortalityEpidemiology, 2011
- Medication Adherence in Outpatients With Severe Mental DisordersJournal of Clinical Psychopharmacology, 2010
- Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practiceToxicology and Applied Pharmacology, 2004